Prebiotic scFOS improves body composition for overweight prediabetics: Tereos study
Supplementation with short-chain fructo-oligosaccharides (scFOS) demonstrates modest fat mass reduction and lean mass increase in overweight prediabetics, driven by gut microbiota modulation, not calorie restriction.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 10 February 2026
Daily supplementation with 20 grams of short-chain fructo-oligosaccharides (scFOS) for 12 weeks can modestly improve body composition in overweight prediabetic adults, according to a recent study published in Frontiers in Nutrition. Researchers from Tereos and Biofortis reported decreases in fat mass and increases in lean mass, without requiring caloric restriction or impacting overall body weight. This finding suggests a significant commercial advantage for supplement brands seeking to penetrate the metabolic health and weight management sectors with evidence-backed ingredients.
The study, which used Actilight, a 95% scFOS product from Beghin-Meiji (a Tereos subsidiary), involved 66 overweight prediabetic individuals in a randomised, double-blind, placebo-controlled trial. The observed body composition changes—a 0.26% fat mass decrease in the prebiotic group versus a 0.03% increase in the placebo group, and a 0.27% lean mass increase versus a 0.3% decrease—were not attributed to altered food intake or physical activity. Instead, researchers speculated that gut microbiota modulation and short-chain fatty acid (SCFA) mediated metabolic effects were the primary drivers.
Analysis of gut microbiota revealed a significant increase in beneficial Bifidobacterium and Anaerostipes, alongside reductions in Blautia and Ruminococcus2, the latter often associated with higher BMI and fatty liver disease. Increases in fecal acetate and propionate levels supported these microbial shifts. While glucose metabolism markers showed no significant differences, the sustained improvements in body composition and favourable gut microbiome alterations highlight scFOS's potential as a preventative strategy against obesity and Type 2 Diabetes.
What this means for United Kingdom
UK supplement manufacturers and brand owners can leverage this new clinical data to formulate and market products targeting body composition and metabolic health, particularly for the growing prediabetic population. Robust substantiation for scFOS, demonstrating fat loss and lean mass gain without calorie restriction, provides a strong basis for novel claims under FSA and EFSA guidance, subject to full claim approval. This differentiates products in a competitive market where the MHRA reviews weight management claims rigorously. Procurement leads should assess current scFOS supply chain resilience and pricing, as demand may increase for fully substantiated ingredients. Reformulation windows should be prioritised to capitalise on this emerging evidence, securing early mover advantage for new weight management and gut health product lines.
This study provides compelling evidence for expanding prebiotic applications beyond digestive health. As consumer awareness of the gut-brain-body axis grows, validated ingredients like scFOS offer a pathway for brands to offer comprehensive metabolic support. This research offers valuable insight into the mechanisms of action, reinforcing prebiotics’ role in mitigating metabolic disorders, which aligns with evolving consumer health priorities.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.
This article does not constitute medical advice.